Valemetostat
Hematology
Concentration-QTc analysis of valemetostat in patients with hematologic malignancies
Tachibana M, Poland B, Kakurai Y, Chen Y, Li C, Lau Y.
Clin Transl Sci. 2025 Nov;18(11):e70391. doi: 10.1111/cts.70391.
T-DXd
Breast Cancer
Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer
Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, et al.
N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668.
Valemetostat
Hematology
Effect of valemetostat on the pharmacokinetics of midazolam and digoxin: A phase 1 drug-drug interaction study in patients with non-Hodgkin lymphoma
Tachibana M, Horwitz S, Jacobsen E, et al.
Clin Transl Sci. 2025 Nov;18(11):e70330. doi: 10.1111/cts.70330.
Edoxaban
Cardiovascular - AF
Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the global ETNA-AF Registry
Boriani G, Kirchhof P, de Souza JAG, et al.
Eur J Prev Cardiol. 2025 Oct 25:zwaf685. doi: 10.1093/eurjpc/zwaf685.
T-DXd
Breast Cancer
Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: Plain language summary of the ERICA study
Sakai H, Tsurutani J, Ozaki Y, et al.
Future Oncol. 2025 Nov;21(27):3459-3475. doi: 10.1080/14796694.2025.2566329.
T-DXd
Breast Cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): A randomised, open-label, multicentre, phase III trial
Harbeck N, Modi S, Pusztai L, et al.
Ann Oncol. 2026 Feb;37(2):166-179. doi: 10.1016/j.annonc.2025.10.019.
HER3-DXd
Tumor-agnostic
HERTHENA-PanTumor01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Powles T, Bhatia A, Burtness B, et al.
Future Oncol. 2025;21(25):3283-3292. doi: 10.1080/14796694.2025.2561539.
I-DXd
Lung Cancer
Ifinatamab deruxtecan in patients with extensive-stage small-cell lung cancer: Primary analysis of the phase 2 IDeate-Lung01 trial
Rudin CM, Johnson ML, Paz-Ares L, et al.
J Clin Oncol. 2026 Feb;44(4):261-273. doi: 10.1200/JCO-25-02142.
Valemetostat
Hematology
Physiologically based pharmacokinetic modeling of valemetostat to inform dose recommendations when coadministered with CYP3A/P-gp modulators
Watanabe A, Okudaira N, Tachibana M, et al.
Clin Transl Sci. 2025;18(10):e70333. doi: 10.1111/cts.70333.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: Long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Modi S, Jacot W, Iwata H, et al.
Nat Med. 2025 Dec;31(12):4205-4213. doi: 10.1038/s41591-025-03981-4.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32